Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
49 studies found for:    BIBF 1120 | Phase 2
Show Display Options
Rank Status Study
1 Recruiting BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: BIBF 1120
2 Active, not recruiting Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer
Intervention: Drug: BIBF 1120
3 Withdrawn A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
Conditions: Small Cell Lung Cancer;   Platinum-sensitive
Intervention: Drug: BIBF1120
4 Active, not recruiting Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Condition: Carcinoma, Renal Cell
Interventions: Drug: BIBF 1120;   Drug: sunitinib
5 Recruiting Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC)
Condition: Breast Cancer
Interventions: Drug: BIBF 1120;   Behavioral: Phone Call
6 Unknown  BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
Condition: Urothelial Carcinoma
Intervention: Drug: BIBF1120
7 Recruiting Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Conditions: Lung Cancer;   Lung Metastases
Interventions: Drug: Nintedanib;   Drug: Prednisone;   Other: Placebo
8 Unknown  BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer;   Small Cell Lung Cancer Recurrent
Intervention: Drug: BIBF 1120
9 Active, not recruiting Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Condition: Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Intervention: Drug: BIBF1120
10 Completed Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
11 Completed A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: BIBF 1120 low dose;   Drug: BIBF 1120 high dose
12 Completed
Has Results
BIBF 1120 for Recurrent High-Grade Gliomas
Conditions: Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
Intervention: Drug: BIBF 1120
13 Completed
Has Results
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: BIBF 1120;   Drug: mFolfox;   Drug: Bevacizumab;   Drug: mFolfox 6;   Drug: bevacizumab
14 Recruiting Nintedanib(BIBF1120) in Thyroid Cancer
Conditions: Medullary Thyroid Cancer (MTC);   Differentiated Thyroid Cancer (DTC)
Interventions: Drug: Nintedanib;   Drug: Placebo
15 Completed
Has Results
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib;   Drug: BIBF 1120
16 Completed BIBF 1120 in Recurrent Glioblastoma Multiforme
Condition: Recurrent Glioblastoma
Intervention: Drug: BIBF1120
17 Completed
Has Results
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Placebo;   Drug: BIBF 1120
18 Completed Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF 1120 ES low dose;   Drug: BIBF 1120 ES high dose;   Drug: Placebo to BIBF 1120 ES
19 Completed A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Condition: Colorectal Neoplasms
Intervention: Drug: BIBF 1120 and BIBW 2992
20 Unknown  TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
Condition: Colorectal Cancer
Interventions: Drug: mFOLFOX6 + BIBF 1120;   Drug: mFOLFOX6+placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.